Biocon Biologics may close $3.34 billion Viatris deal in Q1

By cineramaMay 1, 2022DeFi

Kiran Mazumdar-Shaw, chairperson of Biocon told ET that the components of financing the deal such as equity and debt were in place. Biocon Biologics said it can close the […]

Click here to view full article

Disclaimer

The statements, opinions and data contained on this site are solely those of the individual authors and contributors and not of the publisher of www.bitcoinisle.com. All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured primarily from third party sources. We make no warranties of any kind in relation to our content and services, including but not limited to accuracy, security and updatedness. No part of the content and services that we provide constitutes financial advice, legal advice or any other form of advice. Any use or reliance on our content and services is solely at your own risk and discretion. You should conduct your own research, review, analyze and verify our content and services before relying on or using them. Participating in cryptocurrency activities is a highly risky endeavor, please therefore consult your financial advisor before making any monetary decisions. No content on our Site is meant to be a solicitation or offer.

Biocon Biologics may close $3.34 billion Viatris deal in Q1

Tags:

Breaking News…

Previous PostEthereum Whale Moves 13,757 ETH Off Gemini

Next PostValue Locked in Defi Drops Below $200 Billion, April's Dex Trade Volume Drops 21% Lower Than March

Disclaimer